Molecular analysis and risk factors for escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Cornejo Juárez, Patricia ^a   Pérez Jiménez, Carolina ^a   Silva Sánchez, Jesús ^b   Velázquez Acosta, Consuelo ^a   González Lara, Fernanda ^a   Reyna Flores, Fernando ^b   Sánchez Pérez, Alejandro ^b   Volkow Fernández, Patricia ^a  

^a SECRETARÍA DE SALUD   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOODSTREAM INFECTION; CONTROLLED STUDY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; RISK FACTOR; ACUTE DISEASE; BIOSYNTHESIS; ENZYMOLOGY; ESCHERICHIA COLI INFECTION; FEMALE; GENETICS; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; LEUKEMIA; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY;

ANTIINFECTIVE AGENT; BETA LACTAMASE;

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84859962764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035780     Document Type: Article

References (31)

1. Peña C, Gudiol C, Calatayud L, Tubau F, Dominguez MA, Pujol M, et al. (2008) Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalized patients: factors influencing mortality. J Hosp Infect 68: 116-122.
2. Gudiol C, Calatayud L, García-Vidal C, Cisnal M, Sanchez-Ortega I, et al. (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65: 333-341.
3. Garza-González GE, Mendoza Ibarra SI, Llaca-Díaz JM, González GM, (2011) Molecular characterization and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates at a tertiary-care centre in Monterrey, Mexico. J Med Microbiol 60: 84-90.
4. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, et al. (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58: 299-307.
5. Blot F, Nitenberg G, Brun-Buisson C, (2000) New tools in diagnosing catheter-related infections. Support Care Cancer 8: 287-292.
6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM, (1988) CDC definitions for nosocomial infections. Am J Infect Control 16: 128-140.
7. Clinical and Laboratory Standards Institute (2006) Performance Standards for Antimicrobial Susceptibility Testing. Vayne, PA, USA.
8. Kaufmann ME, (1988) Pulse-field gel electrophoresis. Methods Mol Med 15: 17-31.
9. Akpaka PE, Legall B, Padman J, (2010) Molecular detection and epidemiology of extended-spectrum beta-lactamase genes prevalent in clinical isolates of Klebsiella pneumoniae and E. coli from Trinidad and Tobago. West Indian Med J 59: 591-596.
10. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, et al. (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33: 2233-2239.
11. Kieser T, (1984) Factors affecting the isolation of CCC DNA from Streptomyces lividans and Escherichia coli. Plasmid 12: 19-36.
12. Pérez F, Endimiani A, Hujer KM, Bonoma RA, (2007) The continuing challenge of ESBLS. Curr Opin Pharmacol 7: 459-469.
13. Coque TM, Barquero F, Cantón R, (2008) Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. (Abstract). Euro Surveill 13 (pii): 19044.
14. Paterson DL, Bonomo RA, (2005) Extended spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18: 657-686.
15. Yu WL, Chuang YCH, Rasmussen JW, (2006) Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 39: 264-277.
16. Miranda G, Castro N, Leaños B, Valenzuela A, Garcia-Ramos U, et al. (2004) Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended-spectrum beta-lactamase in a Mexican pediatric hospital. J ClinMicrobiol 42: 30-35.
17. Silva J, Gatica R, Aguilar C, Becerra Z, Garza-Ramos U, et al. (2001) Outbreak of infection with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a Mexican hospital. J Clin Microbiol 39: 193-196.
18. Mosqueda-Gómez JL, Montano-Loza A, Rolon AL, Cervantes C, Bobadilla-del-Valle JM, et al. (2008) Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. A case-control study. Int J Infect Dis 12: 653-659.
19. Silva-Sánchez J, Garza-Ramos JU, Reyna-Flores F, Sanchez-Perez A, Rojas-Moreno T, et al. (2011) Extended-spectrum beta-lactamase-producing Enterobacteriaceae causing nosocomial infections in Mexico. A retrospective and multicenter study. Arch Med Res 42: 156-162.
20. Chong Y, Yakushiji H, Ito Y, Kamimura T, (2010) Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int J Infect Dis 14 (Suppl 3): e171-e175.
21. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Cueto M, et al. (2008) Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 14: 180-183.
22. Ramphal R, Ambrose PG, (2006) Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 42: S164-S172.
23. Wu UI, Wang JL, Chen WC, Chang SC, Chen YC, (2011) Risk factors and outcomes of Escherichia coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum-beta-lactamases. Eur J Clin Microbiol Infect Dis 30: 33-39.
24. Hu B, Ye H, Xu Y, Ni Y, Hu Y, et al. (2010) Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Curr Med Res Opin 26: 1443-1449.
25. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, et al. (2005) Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Arch Inter Med 27: 1375-1380.
26. Peña C, Gudiol C, Tubau F, Sabalis M, Pujol M, et al. (2006) Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalized patients. Clin Microbiol Infect 12: 279-284.
27. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO, (2001) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32: 1162-1171.
28. Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, et al. (2009) Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 27: 1-8.
29. Wang FD, Lin ML, Liu CY, (2005) Bacteremia in patients with hematological malignancies. Chemotherapy 51: 147-153.
30. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, et al. (2004) Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 42: 4769-4775.
31. Garza-Ramos U, Martinez-Romero E, Silva-Sanchez J, (2007) SHV-type extended-spectrum beta-lactamase (ESBL) are encoded in related plasmids from enterobacteria clinical isolates from Mexico. Salud Publica Mex 49: 415-421.